OWC Pharmaceutical Research Corp (OWCP)

[GOIN/Green]

Here is the newest update/answers based on what is communicated by the company.

Cheers!

Claim: "Why doesn't OWCP submit patent applications to the USPTO?

I think we all know - OWCP couldn't deal with the rigors of the FDA and the patent applications"

Claim Rejected: Check out USTPO website for a family of 9 registered patents and a total of 31 patents.
Claim: “I guarantee they will never post the patent applications..”

Claim Rejected: Just check out USPTO and other international patent registration sites. here is one! https://www.uspto.gov/patents-application-process/search-patents


Claim: “Registered patents are meaningless”

Claim Rejected: MIT Scientists’ information on the importance of patent registrations…

http://web.mit.edu/e-club/hadzima/the-importance-of-patents.html


Claim: “all patent claims submitted to the USPTO have been rejected"

Claim Rejected: They are still there on the website, just updated like thousands of other companies’ patents. GW** last patent took 5 years of updates to finally get granted.

https://www.uspto.gov/patents-application-process/search-patents


Claim: “There is zero proof that OWCP has done any clinical trials/studies.”

Claim: “you have absolutely no proof that Sheba is doing any research with OWCP”.

Claim Rejected: Careful Reading required!

"OWC Pharmaceutical Research Corp. (“OWC”) through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., announces the successful completion of the first part of its Phase I, placebo controlled, maximal dose study (the “Psoriasis Study”) to determine the safety and tolerability of topical ointment containing medical grade cannabis (the “Topical Ointment”) in healthy volunteers. The study is being performed by Professor Aviv Barzilai, Director of the Department of Dermatology at Chaim Sheba Medical Center. Sheba is a university-affiliated hospital that serves as Israel’s national medical center and is one of the leading integrated medical centers in the Middle East. The completed part of the study consisted of application of escalating doses of the Topical Ointment to healthy volunteers and was successfully completed with no adverse effects. After completion of the second part of this study, the company plans to initiate a phase II clinical study to demonstrate the efficacy of Topical Ointment in treating mild to moderate psoriasis and other inflammatory skin diseases.


Claim: “There are 7 patents that have been applied for in multiple places”


Claim Rejected:
Much better than "no patent" baseless claim. Good!

$OWCP USPTO Patent link (9 patent families, 31 patents, and counting) All patents are still active. These registered patents are being updated.

United States Patent and Trademark Office (USPTO)

https://www.uspto.gov/patents-application-process/search-patents

Claim: "OWCP has to file a S-1 and the SEC has to declare it effective - with OWCP being investigated by the SEC it will never be deemed effective"

Claim Rejected: SEC already declared S-1 effective! smile

Claim: “The S-1 being declared effective is harmful to shareholders”

Claim Rejected:
Thousands of companies yet go through a lot of pain to get their S-1 approved so they can issue shares to get funded to continue their business operations?

Claim: “First, the $5 million isn't guaranteed - you need to read the Equity Purchase Agreement - OWCP has to file a S-1 and the SEC has to deem it effective - that won't happen since there is a ongoing investigation. “

“OWCP has 60 days to file a S-1.”
Then, quietly after SEC approved $OWCP S-1…
Claim Rejected by ITSELF!: “OWCP doesn't receive $5 million in one lump sum - it is in tranches”

Claim: “The massive dilution has begun with the filing of Form 424B3!”

Claim Rejected Priced at 0.2 and 0.22

April 2018 Private Placement

On April 30, 2018, we entered into and consummated a Securities Purchase Agreement (the “Purchase Agreement”) with a non-US-based institutional investor (the “Investor”). Under the terms and conditions of the Purchase Agreement, we sold and the Investor bought, (i) 500 shares of our new series of preferred stock designated as Series A Preferred Stock (the “Series A Preferred Shares”), which, as of April 30, 2018, were convertible into 25,000,000 shares of our common stock at a conversion price of $0.20 per share, subject to adjustment pursuant to the anti-dilution provisions of the Preferred Shares, and (ii) warrants representing the right to acquire 12,500,000 shares of our common stock at an exercise price of $0.22 per share (the “Warrants”), subject to adjustment pursuant to the anti-dilution provisions of the Warrants, for an aggregate purchase price of $5,000,000

Claim: “ they were lead to believe that OWCP owned 7 patents“

Claim rejected itself: “There are 7 patents that have been applied for in multiple places”

Claim: “The latest storyline is that the "psoriasis cream" has completed Phase 1 studies “

Claim Rejected: The correct storyline is that the psoriasis cream has completed the Part 1 of Phase 1 studies.

Claim: “OWCP has not done any new research since 2014.”

Claim Rejected: Check out the updates on USPTO and WIPO sites. Many company's research has been updated there in 2018. This is the newest one. Multiple Myeloma US Patent Application has been published on 7/5/2018.


https://patentscope.wipo.int/search/en/detail.jsf?docId=US222841762&recNum=1&tab=NatCollDocuments&maxRec=32&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString="one+world+cannabis";;;;